Phase II trial of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in patients with NSCLC of squamous histology who have progressed on prior therapy

Trial Profile

Phase II trial of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in patients with NSCLC of squamous histology who have progressed on prior therapy

Planning
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2015

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors BIND Therapeutics
  • Most Recent Events

    • 22 Dec 2014 New trial record
    • 19 Nov 2014 This global trial is being planned, according to a BIND Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top